SCHEMBL22492047

SCHEMBL22492047

O=C(O)C1CC(F)CCC1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.49
AKR1C3 P42330 1/20 0.46
AKR1C1 Q04828 1/20 0.46
HDAC4 P56524 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 2/20 0.43
SLC9A1 P19634 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
DEGS1 O15121 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6466566 0.86 FFAR1 (0.56) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL1073458 0.85 AKR1C3 (0.55) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL15590483 0.85 AKR1C3 (0.55) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL5217474 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL8295172 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL323824 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL2034678 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL323823 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL4126470 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1
SCHEMBL5315326 0.79 FFAR1 (0.70) FFAR1AKR1C3AKR1C1HDAC4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 LES LABORATOIRES SERVIER (FR) 2022-05-17 US disclosed
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 LES LABORATOIRES SERVIER (FR) 2020-12-31 US disclosed
EP-3717482-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Les Laboratoires Servier SAS (FR) 2020-10-07 EP disclosed
CN-111542524-A Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 法国施维雅药厂 2020-08-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 USP7, PSMA7, PSMB7 FFAR1 3726/4885AKR1C3 3208/4885AKR1C1 3656/4885
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 PSMB7, PSMA7, USP7 FFAR1 4160/4885AKR1C3 3210/4885AKR1C1 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.